Wells Fargo says its Outperform rating on Walgreens Boots Alliance Inc (NASDAQ: WBA) isn't contingent on the closing of Rite Aid Corporation (NYSE:
RAD) deal even as it believes the accretive acquisition would
propel Walgreens to the largest market share again.
“We believe Walgreens is positioned to benefit from favorable demographics with an aging population and increasing use of
pharmaceuticals,” analyst Peter Costa wrote in a note.
Costa says Walgreens’s acquisition of Alliance Boots, and recent strategic Pharmacy
Benefit Manager partnerships bodes well for market share gains and long-term EPS growth.
“If the RAD deal were to fall
through, we expect the capital freed up could provide other capital deployment opportunities including strategic investments
and potential acquisitions,” Costa added.
The comments came after the companies amended and
extended the merger termination date to July 31 from January 27.
The amendment also cuts the purchase price paid to Rite Aid to $6.50-7.00 per share in cash from $9.00 per share in the initial
agreement.
The amendment also implies the recently announced plans to sell 865 Rite Aid stores to
Fred's, Inc. (NASDAQ: FRED) were not enough
to address potential antitrust concerns.
Walgreens expected Rite Aid acquisition to be $0.05 $0.12 accretive to adjusted FY17 EPS.
At last check, shares of Walgreens were down 0.28 percent to $81.27, while shares of Rite Aid plunged about 17 percent to $5.78
after setting a new 52-week low of $5.70.
Image:
Mike Mozart, Flickr
Latest Ratings for RAD
| Date |
Firm |
Action |
From |
To |
| Apr 2016 |
Deutsche Bank |
Downgrades |
Buy |
Hold |
| Mar 2016 |
Credit Suisse |
Assumes |
|
Outperform |
| Jan 2016 |
Evercore ISI Group |
Downgrades |
Buy |
Hold |
View More Analyst Ratings for
RAD
View the Latest Analyst Ratings
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.